What if the next generation of epigenetic diagnostics ran on a test you helped designing?

Tagomics is a Cambridge-based biotechnology company developing a next‑generation multi‑omic biomarker discovery platform to transform how disease and drug safety are understood, measured, and monitored.

Originating from pioneering research by Dr Robert Neely and colleagues at the University of Birmingham, our proprietary technology integrates genetic, epigenetic, and fragmentomic features from circulating cell‑free DNA. Combined with advanced bioinformatics and machine learning, this enables deep biological insight across applications ranging from early cancer detection to drug safety and organ health monitoring. We have the science, the funding, and the momentum, and we’re now building the production‑grade engineering platform for our first products. To achieve this, we are expanding our multidisciplinary team at Babraham Research Campus, one of Europe’s leading life‑science h...